Targeting of the innate immunity/inflammation as complementary anti-tumor therapies

Research output: Contribution to journalArticlepeer-review


Different types of cancer take advantage of inflammatory components to improve their life-span in the organs. A sustenance of growth factors and cytokines (e.g. interleukin (IL)-1, tumor necrosis factor, IL-6, vascular endothelial growth factor) supports malignant cell progression and contributes to suppress the body immune defense. Strategies to modulate the host micro-environment offer new approaches for anti-cancer therapies. For these reasons new molecules with anti-tumor and anti-inflammatory features (e.g. trabectedin) are looked at with new eyes in the light of the crucial link between inflammation and cancer.

Original languageEnglish
Pages (from-to)581-593
Number of pages13
JournalAnnals of Medicine
Issue number8
Publication statusPublished - Dec 2011


  • Angiogenesis
  • Anti-inflammatory drugs
  • Chemokines
  • Cytokines
  • Inflammation and cancer
  • Tumor-associated macrophages

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Targeting of the innate immunity/inflammation as complementary anti-tumor therapies'. Together they form a unique fingerprint.

Cite this